10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Drug major Takeda Pharmaceutical today announced a geographically-focused exclusive collaboration and license agreement with fellow Japan-based JCR Pharmaceuticals to commercialize JR-141 (pabinafusp alfa). 1 October 2021
High-risk MDS, often referred to as preleukemia, is a chronic form of blood cancer with a significant level of unmet medical need. While no new therapies have been approved in over a decade, that may be about to change, with multiple drugmakers making significant progress. 1 October 2021
Swiss pharma giant Roche has confirmed positive data from the Phase II/III 2066 study of Ronapreve (casirivimab and imdevimab) in patients hospitalized with COVID-19. 1 October 2021
The recent ruling in favor of upholding Amgen’s patents for its phosphodiesterase inhibitor Otezla (apremilast) until its patent expiry in 2028 is an important safeguard for US biotech giant Amgen. 1 October 2021
Autogene cevumeran, an innovative cancer vaccine which could pave the way for a new class of oncology treatment, has entered into Phase II testing. 1 October 2021
Following French pharma major Sanofi’s decision this week to drop out of the race to develop coronavirus vaccines because it admits to being a late comer, the charity Médecins Sans Frontières (MSF) is urging the company to transfer the technology and know-how for the vaccine to the World Health Organization (WHO)-led COVID-19 mRNA vaccine technology transfer hub in South Africa. 1 October 2021
The Russian government, together with the Federal Antimonopoly Service (FAS), have agreed to raise prices for more than 30 drugs from the list of vital and essential since January of the current year, reports The Pharma Letter’s local correspondent. 1 October 2021
In the UK, a positive reimbursement decision has paved the way for certain people with advanced thyroid cancer to receive treatment with Eli Lilly’s Retsevmo (selpercatinib). 1 October 2021
Rumors that US pharma giant Merck & Co was interested in acquiring Acceleron Pharma proved to be well-founded after an $11.5 billion deal was confirmed today. 30 September 2021
German life sciences company Merck KGaA today announced a mutual decision with UK pharma major GlaxoSmithKline to terminate their agreement on bintrafusp alfa, effective September 30, 2021. 30 September 2021
Danish dermatology specialist LEO Pharma today announced results showing that after two years of continuous treatment with Adtralza (tralokinumab), adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference. 30 September 2021
Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), has written to the UK’s Chancellor of the Exchequer, Rishi Sunak, outlining the case for investing in pharma. 30 September 2021
Positive results from a Phase IIa study evaluating the safety and efficacy of amlitelimab (formerly KY1005), a human monoclonal antibody targeting key immune system regulator OX40-Ligand, were presented as a late-breaker today at the European Academy of Dermatology and Venerology (EADV) 2021 Virtual Congress. 30 September 2021
US biotech Amicus Therapeutics is to create a new genetic medicine company called Caritas Therapeutics as part of a deal that will see its gene therapy business acquired by ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company (SPAC). 30 September 2021
As September, Duchenne Action Month, comes to a close, we take a look at advances in pharmacological treatments for this rare condition. 30 September 2021
A global licensing agreement between Sunovion Pharmaceuticals and Japan’s Otsuka Pharmaceutical (TYO: 4578) will see the firms jointly develop and sell four compounds in neuropsychiatry. 30 September 2021
Indian drugmaker Glenmark Pharmaceuticals today announced it has received marketing approval for its fixed-dose combination nasal spray Ryaltris (olopatadine Hcl and mometasone furoate), in 13 countries across the European Union and the UK. 30 September 2021
Mirum Pharmaceuticals, a leader in rare liver disease, says that the US Food and Drug Administration has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. 30 September 2021
On Wednesday, the US Food and Drug Administration issued the draft guidance for industry, “Benefit-Risk Assessment for New Drug and Biological Products.” 30 September 2021
Cuba is keen to forge joint ventures (JVs) with Indian companies for manufacturing biotech drugs and vaccines. A new joint venture established in Cuba is offering opportunities to Indian pharma and biotech companies for investments and partnerships. 29 September 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024